Population Genomic Screening for Three Conditions Likely Cost-Effective

TUESDAY, May 9, 2023 (HealthDay News) -- Conducting screening tests for three common genetic disorders could be cost-effective at a population level for adults younger than 40 years of age, according to a study published online May 9 in the Annals of Internal Medicine.
Gregory F. Guzauskas, M.S.P.H., Ph.D., from the University of Washington in Seattle, and colleagues estimated the cost-effectiveness of simultaneous genomic screening for Lynch syndrome, hereditary breast and ovarian cancer syndrome, and familial hypercholesterolemia in separate age-based cohorts of racially and ethnically representative U.S. adults.
The researchers found that screening 100,000 unselected 30-year-olds resulted in 101 and 15 fewer overall cancer cases and cardiovascular events, respectively, and an increase of 495 quality-adjusted life years (QALYs) at an incremental cost of $33.9 million in the base-case analysis. Per QALY gained, the incremental cost-effectiveness ratio was $68,600. In a sensitivity analysis, screening 30-, 40-, and 50-year-old cohorts was cost-effective in 99, 88, and 19 percent of probabilistic simulations, respectively, at the threshold of $100,000 per QALY. Screening 30-, 40-, and 50-year-olds reached this threshold at test costs of $413, $290, and $166, respectively. Highly influential parameters included prevalence of variants and adherence to preventive interventions.
"Our analysis indicates that screening with a limited panel of high-evidence genes associated with three U.S. Centers for Disease Control and Prevention Tier 1 conditions is likely to be cost-effective with an appropriate test cost for U.S. adults younger than 40 years," the authors write.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Una mujer usó pastillas para un aborto médico, pero tenía un peligroso embarazo ectópico
JUEVES, 19 de enero de 2023 (HealthDay News) -- Tras las decisión de la Corte...
U.S. Buys 600,000 Doses of New COVID Treatment Still Awaiting FDA Approval
FRIDAY, Feb. 11, 2022 (HealthDay News) -- The U.S. government has bought 600,000...
Dying Young From Heart Disease: Where You Live in the U.S. Matters
TUESDAY, Oct. 19, 2021 (HealthDay News) -- People who live in disadvantaged...
Meat Intake After Diagnosis Not Tied to Colon Cancer Outcomes
WEDNESDAY, March 2, 2022 (HealthDay News) -- Intake of unprocessed red meat or...
